Glycosylation of cell surface receptors: tunicamycin treatment decreases insulin and growth hormone binding to different levels in cultured lymphocytes.
D002460:Cell Line; D002462:Cell Membrane / Q000378:metabolism; D005944:Glucosamine / Q000031:analogs & derivatives*; D006023:Glycoproteins / Q000096:biosynthesis; D013006:Growth Hormone / Q000378:metabolism*; D006801:Humans; D007328:Insulin / Q000031:analogs & derivatives / Q000378:metabolism*; D007700:Kinetics; D008214:Lymphocytes / Q000378:metabolism*; D008565:Membrane Proteins / Q000096:biosynthesis; D011972:Receptor, Insulin / Q000187:drug effects / Q000378:metabolism*; D011956:Receptors, Cell Surface / Q000187:drug effects / Q000378:metabolism*; D011986:Receptors, Somatotropin; D014415:Tunicamycin / Q000494:pharmacology*
D006023:Glycoproteins; D007328:Insulin; D008565:Membrane Proteins; D011956:Receptors, Cell Surface; D011986:Receptors, Somatotropin; C008147:insulin, iodo-; D014415:Tunicamycin; D013006:Growth Hormone; D011972:Receptor, Insulin; D005944:Glucosamine